Brought to you by 
Janssen licenses rights to Eisai's proton pump inhibitor
13 Jul 1999
Executive Summary
J&J's Belgian subsidiary Janssen will co-promote Japanese pharmaceutical company Eisai's proton pump inhibitor, Pariet (rabeprazole), in the US, UK, Germany, and France.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Janssen licenses rights to Eisai's proton pump inhibitor
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice